-> Biomarker testing

KRAS mutations in lung cancer: Are we close to targeting the untargetable?

The success we have seen with targeted therapeutics for EGFR-mutated or ALK-rearranged lung cancers has not been demonstrated in KRAS-positive tumors. I am really excited that that’s changing. We are finally at the cusp of promising new treatment approaches directed toward the KRAS gene mutation. Some of these approaches are already moving toward clinical trials.

– Pasi Jänne, MD, PhD

Dr. Pasi Janne

Targeting the KRAS mutation – An old target with new angles!

Dr. Timothy BurnsAfter losing both parents to lung cancer, Dr. Timothy Burns, now an oncologist and researcher specializing in lung cancer at the University of Pittsburgh, committed himself to searching for better treatment options for lung cancer patients.

Because the KRAS mutation is found in 25% of lung cancer patients and there still isn’t a therapy that effectively targets the mutation, Dr. Burns focuses his research on KRAS.

Combining biomarkers with PET scans—a “one-stop shop” for lung cancer early detection

Viswam Nair, MDEach year Viswam Nair, MD, manages treatment plans for hundreds of patients at Stanford University. A pulmonologist with formal training in epidemiology, Dr. Nair stays current on the latest scientific breakthroughs to offer his patients the best possible outcomes.

A Survivor’s Experience with Biomarker Testing and TKI Treatments

Back in 2013, when Dan Cadigan was first diagnosed with stage III lung cancer, his treatment options were limited to surgery followed by chemotherapy. However, at his one-year follow-up scan, they found nodules in both lungs and he was diagnosed with stage IV recurrent cancer.

Normally, it would have meant a return to chemo for treatment.

Working Toward a Blood Test to Predict Immunotherapy Success

Immunotherapy, the treatment that harnesses the body’s natural defenses to fight disease, has helped patients, excited imaginations, and stimulated new avenues of research in lung cancer. While approximately 40-50 percent of advanced-stage non-small cell lung cancer (NSCLC) patients are likely to benefit from immunotherapy, some patients may be at increased risk for side effects from immunotherapy or may have better outcomes through other treatment options.  

Looking for Biomarkers to Predict Response to Immunotherapy

Over the past several years, Jeffrey Thompson, MD, MS, watched eagerly as checkpoint inhibitors, immunotherapy drugs that take the brakes off the immune system to allow the body to fight disease more efficiently, were approved in the front-line setting for lung cancer. However, a question kept nagging at the back of his mind: Why do approximately 40-50 percent of advanced-stage non-small cell lung cancer (NSCLC) patients respond so well to immunotherapy while others do not?